Latest News
Search News
Going virtual for BCI PhD Day 2020
7th October 2020
On 23rd September 2020, Barts Cancer Institute held their annual PhD Day, which is a celebration of the work of our postgraduate research students and an opportunity for them to showcase their research to fellow students and academics. Due to the ongoing coronavirus pandemic, this year’s PhD Day took place online via Zoom, and 130 staff and students tuned in to watch the live presentations by our students.
Read more
London Pancreas Workshop 2020
30th September 2020
On 11th September 2020, Professors Hemant Kocher and Nick Lemoine hosted the eighth London Pancreas Workshop (LPW) – a forum for state-of-the-art clinical and basic research in pancreatic cancer. In a first for the biennial event, this year’s LPW took place online with pre-recorded speaker presentations and live, interactive Q&A sessions.
Read more
Research explainer with Dr Gabriella Ficz
28th September 2020
We spoke with Dr Gabriela Ficz to find out about her recent publication in Nature Communications. The study set out to determine how embryonic stem cells can acquire features that are found in cancer cells.
Read more
Results from the Phase I STARPAC trial
24th September 2020
A treatment combination involving the addition of a form of vitamin A to the current standard treatment regimen for pancreatic cancer is safe for patients, according to an early phase clinical trial led by Professor Hemant Kocher from Barts Cancer Institute, Queen Mary University of London.
Read more
Congratulations to Vinaya Srirangam Nadhamuni
22nd September 2020
BCI PhD student wins People’s Choice Award at thesis competition national final Congratulations to Vinaya Srirangam Nadhamuni, Clinical Research Fellow at Barts Cancer Institute (BCI), Queen Mary University of London, […]
Read more
Immunotherapy for advanced bladder cancer
18th September 2020
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles.
Read more